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 1. Introduction 
 
Over the past few years, the ability to readily harvest the extracellular matrix (ECM) of cells 
has experienced many innovative developments that have led to an increase in the availability of 
ECM for study and experimentation.  This accessibility along with the long standing history of 
the ECM as a potential biomaterial has turned into a growing movement to utilize and apply the 
ECM and its byproducts to biomedical research and therapies [1].  A breadth of applications has 
emerged spanning uses such as three-dimensional scaffolds in cell culture research to direct 
medical procedures implemented as fillers for ostechondral defects and the creation of cardiac 
and vasculature reconstructive tissue for implantation [2].  The adaptable nature of the ECM 
along with its favored properties of biodegradation and biocompatibility make it highly desirable 
as an implantable biomaterial, but problems have arisen during its implementation that have 
hampered its therapeutic potential.  In particular, one of the greatest benefits with of ECM-based 
implantations may also be one of the greatest limiting factors –the short time in which it is 
biodegraded or resorbed [3].  As the body has the ability to produce ECM, so it too possesses the 
ability to resorb it which it readily does when large quantities of implanted ECM are introduced 
in vivo.  A pharmaceutical or chemical treatment to improve the functional time of implantable 
ECM is potentially available, but there exists a need for a cost effective, in vitro model to 
evaluate these inhibitory agents for their ability to hamper ECM degradation.   
 
1.1 The Physiological Environment of Extracellular Matrix 
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 The extracellular matrix is not definable by its material alone as its composition can differ 
depending on the microenvironment of the body or organism that houses it.  Instead, the ECM is 
most definable by its functional characteristics including its abilities to allow cellular adhesion, 
provide structure, and even act as a repertoire for intercellular signals such as growth factors [3].  
That being said, all ECM shares some common compositional components with the most 
abundant of these being the structural proteins- collagen and elastin- and the adhesive proteins- 
fibrinogen and laminin [4].  In particular, collagen is the most common underlying protein found 
in ECM comprising up to 90% of the dry weight in some tissues [5].  Collagen is subdivided into 
twenty-eight types to better distinguish among its structures and functions.  The most widespread 
of these functioning in the ECM are types I and III [5] utilized in a span of biological locations 
ranging from structure of skin, vasculature, interstitial tissue, granulation tissue and scar tissue 
[6].  Due to this prevalence throughout the body, collagen is one of the major targets of 
reconstruction since it comprises most of the structure of the ECM.  It was for this reason that the 
model system to evaluate ECM degradation used DQ collagen as an analog.  DQ collagen is a 
collagen conjugate molecule that susceptible to all the same enzymes of natural collagen (Figure 
1).  It is conjugated with a fluorescent molecule that is only exposed when the DQ collagen is 
cleaved, allowing variations in the level of collagen degradation to be evaluated by measuring 
changes in expressed fluorescence [7].  The molecules that cause this degradation are naturally 
occurring proteins called matrix metalloproteases (MMP) which can be found anywhere there is 
ECM reconstruction.  
3 
 
  These MMPs operate with the use of a catalytic Zn2+ active site in their structure 
allowing the hydrolysis of ECM proteins [8].  The MMP group that specifically degrades 
collagen is known as the collagenases.  The collagenases operate as endopeptidases cleaving 
collagens I, II, and III at an interior-domain site marked by the N-terminus [8].  Due to the 
effectiveness of MMPs at low concentrations over short time intervals, they are synthesized as 
zymogens that must have a section of the pro-peptide domain removed in order for the zinc-
dependent active site to become available [8].  In addition, members of another family of 
proteins known as the tissue inhibitors of metalloproteinase (TIMPs) are produced in areas of 
reconstruction to keep MMP activity in check.  Physiological conditions of reconstruction that 
lead to matrix metalloproteases synthesis are angiogenesis, wound healing, and tissue 
remodeling for growth or normal wear.   
 The cells responsible for ECM reconstruction are known as fibroblasts.  These cells 
produce and export both the proteins that comprise the ECM as well as the MMPs that help 
remove them.  To accommodate this high level of protein secretion, fibroblasts are characterized 
by extensive endoplasmic reticulum and long, branched cytoplasm.  Their primary goal is to 
Figure 1. Representation of DQ collagen structure before and after degradation by MMPs.  Before degradation, fluorescent 
signal is quenched by close proximity of fluorescent molecules on the intact collagen [7].  As MMPs degrade the collagen 
structure, more fluorescent molecules are exposed resulting in a greater signal.  Ownership of graphic belongs to 
http://aetherforce.com/how-fluorescent-light-works/. 
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 maintain the structure of the ECM and as such they are found in connective tissues and in sites of 
wound healing.  In the model of ECM degradation, 3T3 cells were used as analogs for a potential 
reconstructive environment.  The 3T3 cells are fibroblasts capable of both ECM secretion and 
the ability to secrete collagen degrading MMPs that are necessary to break down the structure of 
DQ collagen [9]. 
 
1.2 Potential Control Mechanisms for Degradation of Extracellular Matrix Implants 
 
In order to lengthen the functional time of implantable ECM, the mechanism of 
degradation must be inhibited.  The matrix metalloproteases are the primary method by which 
ECM is broken down, and the TIMP family of proteins exists as proof that inhibition of these 
proteases is possible naturally.  In particular, the glycoprotein TIMP-1 plays an inhibitory role 
with most of the MMPs including the collagenases [10].  Furthermore, there exist synthetic or 
chemical molecules that likewise inhibit the catalytic actions of MMPs.  One such molecule is 
Batimastat (BB-94) which has been proven to be a dose dependent inhibitor of MMPs during the 
inflammatory response [11].  In order to evaluate the potential to increase the effective time of 
ECM based implants, an in vitro assay was developed to monitor the natural degradation rate of 
ECM in culture with DQ collagen and 3T3 fibroblasts.  The protein TIMP-1 and the molecule 
BB-94 were incorporated into this model to evaluate their potential use in controlling the 
degradation rate of ECM implants. 
 
2. Methods 
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 2.1 Preparation of Foam Scaffold and Well Plates 
 
Foam scaffolds were prepared by first creating a polymer solution of polyurethane and 
DMAC.  The solution was prepared with 2g of polyurethane beads being allowed to dissolve 
completely in 20 mL of DMAC over a 24 hour period.  The next step involved mixing 10 grams 
of table sugar with 200 μL of deionized water to create a sugar slurry.  The sugar slurry was 
spread into molds -dimension 15 mm diameter by 1 mm height- sized for use in twenty-four well 
plates.  The molds were then placed into an oven at 60 degrees centigrade for 20 minutes to 
allow some of the excess water to evaporate off.  At this point the polymer solution was applied 
to sugar filled molds until the molds were filled.  This required between an average of 1.2 to 1.4 
mL of polymer solution per well.  The polyurethane foams were then submerged in deionized 
water for 24 hours at room temperature.  Following the first 24 hour period, the now solid and 
porous polyurethane foams were removed from their molds and placed in a separate DI water 
bath at room temperature.  The new bath was stirred constantly, and the DI water was changed 
every 8 hours for another 24 hour period to remove all traces of remaining sugar.  The foams 
were then removed from the bath and placed 8 apiece into 50 mL centrifuge tubes and allowed to 
freeze overnight in a -25 degree centigrade freezer.  After the foams were completely frozen, 
they were lyophilized for another 24 hours.  The foams were stored sealed at room temperature 
until placed into a twenty-four well plate and sterilized using gas sterilization.   
 
2.2 Cell Culture 
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  Frozen vials of 3T3 fibroblasts were thawed in 37 C water bath and added to 16 mL of 
warm media at same temperature in a T-175 flask.  Following seeding, cells were incubated for 
45 minutes at 37 C.  The media was then removed and replaced so only the cells that adhered to 
the flask would remain.  Cells were incubated at 37 C.  Cells were fed every 24 hours with a 
fresh 17 mL of media until confluence.  Average times of confluence ranged between 5-7 days.   
 Following confluence, cells were then split into three flasks.  After removing all media 
from the flask, trypsin EDTA (7 mL) was added and allowed to incubate with the cells for 15 
minutes.  After this time, 7 mL of warm media were added to neutralize the trypsin.  The 
resulting 14 mL solution was put into a centrifuge vial and spun down at 300 G for 5 minutes.  
The remaining solution was removed and the resulting pellet was re-suspended in 12 mL of 
media.  This new solution was added to 3 T-175 flasks (4 mL each) along with 13 mL warm 
media.  These flasks were cultured using the above steps until confluence.   
 
2.3 Well Plate Preparation 
 
 Foams that had been gas sterilized were treated with fibronectin before cells were seeded 
onto them.  To start, the sterile foams were rinsed with 500 μL of sterile PBS and left to sit for 5 
minutes.  The foams were each rinsed a total of three times.  Fibronectin solution (500 μL) was 
then applied to the foams.  Well plates were wrapped in para-film and stored cold for 36 hours.   
 Cells were removed from T-175 flasks using steps described in 2.2.  Following removal, 
the cells were counted using a hemocytometer.  A total of 8 million cells were seeded per foam 
and warm media was added until the total solution in each individual well was 500 μL.  The well 
plates were then incubated for 24 hours at 37 C.  
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2.4 Testing for Signal to Noise 
 
 Two well plates were used for this test.  One well plate had half of its wells left without 
foams in order to establish controls on the degradation rate of the DQ collagen.  The DQ 
collagen was prepared in three concentrations of 2 μg/mL, 10 μg/mL, and 50 μg/mL.  A total of 
nine foams would be exposed to each concentration over a period of 4 days.  The first three 
foams from each concentration (n=3) would be sampled after 24 hours, the next three foams 
would be sampled after 48 hours, and the final 3 foams would be sampled at 96 hours along with 
each of the foamless control wells.  To sample the wells, three 100 μL samples were taken from 
the 500 μL solution in each well.  The 100 μL samples were put into a 96 well plate.  Fluorescent 
readings were taken on days 1, 2 and 4 with excitation wavelengths at 485/20 nm and emission 
wavelengths at 528/20 nm to best comply with manufacturer’s suggestions.  Foams were 
removed from original plate at time of sampling and placed into a new sterile well plate before 
being suspended in 10% formalin.  DAPI staining was performed on foams to make sure cell 
adhesion had taken place and the well samples were valid (Figure 2).  Test was repeated twice.  
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2.5 Effect of TIMP-1 and BB-94 on MMP Inhibition 
 
Similar to the signal to noise test, two 24 well plates were used for this test.  All foams in 
this test received DQ collagen at the concentration and for the amount of time that yielded the 
greatest signal to noise ratio in the previous tests.  TIMP-1 working solution was prepared with 
sterile PBS to form concentrations of 2 ng/mL, 10 ng/mL, and 100 ng/mL when added to the 500 
μL of media in each well.  Batimistat was made into working solution with DMSO at 
concentrations of 10 nM, 100 nM, and 1000 nM when added to the 500 μL of media in each 
well.  BB-94 solution was added so that the total amount of solution in the well was less than 5% 
DMSO do minimize its effects on the cells.  The DMSO was also sterile filtered to minimize 
chance of contamination.   
One well plate was filled with seeded foams.  Each column corresponded to one of the 
concentrations of BB-94 or TIMP-1 listed above (n=4).  Only eight foams were added to the 
other plate which received no MMP inhibitor.  Samples were taken in the same manner as in 2.4.  
Following the sample collection phase, foams were fixed in 10% formalin in a new well plate.  
Foams were DAPI stained to check for cellular adhesion to the foam.  Sample foams without cell 
adhesion were eliminated from being represented in the final results. 
 
2.6 Statistical Analysis 
Figure 2. Representation of DAPI staining results from the seeded foam scaffoldings that had participated in the assay.  
Foam A is an example of a foam that was successfully seeded as seen by the prevalence of distinguishable nuclei visible on 
the polyurethane foam.  Foam B is an example of a foam that was eliminated from the assay for failure to seed any cells. 
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All data sets are represented by the mean and standard deviation. Comparisons between 
samples groups were evaluated using a student's t-test.  A standard 0.05 level of significance was 
used for all statistical tests. 
 
3. Results 
 
 The first phase of experimentation was 
performed in order to find an acceptable 
signal to noise ratio of testing over a period of 
four days.  Readings were taken on days 1, 2, 
and 4.  The first run had two samples that 
performed differently than the controls at the 
level of statistical significance (Figure 3).  The 
first occurred at day 2 at a concentration of 50 
ug/mL.  The mean value of the sample was 
1612 ± 18.76 while the mean for the control 
was 1409 ± 16.08 giving < 1% chance that the 
two groups were the same.  The second 
notable sample occurred on day 4 at the 
concentration of 50 ug/mL DQ collagen.  The 
mean value of the sample was 2292 ± 102.4 
with the mean of the control being 1427 ± 
Figure 3. Fluorescent values for concentration of DQ 
collagen in presence of fibroblasts, first run.  Only 50 
ug/mL in B and C were shown to be statistically significant 
with signal to noise ratios of about 8:7 and 2:1 
respectively.   
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 50.76 also giving < 1% probability that the two groups were the same.   
 The second run of the assay likewise resulted in two samples that displayed significantly 
different fluorescent values.  However, both of these samples appeared only on the fourth day of 
evaluation (Figure 4).  The first was the 2 
ug/mL concentration of DQ collagen at an 
average of 412 ± 23.96 for the sample and an 
average of 277.7 ± 3.858 giving < 1% chance 
that the sample and control were the same.  
The second was at the 50 ug/mL concentration 
at an average of 2717 ± 233.8 for the sample 
with the control averaging at 2048 ± 31.51 
yielding a probability of < 1% that the two 
groups were the same.  From the above assays 
it was decided that the most substantial signal 
to noise ratio existed at the fourth day at 50 
ug/mL of DQ collagen since both assays 
displayed statistical significance at these 
points.   
 The final test was used to determine 
the effectiveness of BB-94 and TIMP-1 to 
prevent collagen degradation (Figure 5).  From 
the two MMP inhibitors, there were a total of 
three concentrations that were shown to be 
Figure 4. Fluorescent values for concentration of DQ 
collagen in presence of fibroblasts, second run.  Two 
samples in C at 2 and 50 ug/mL were shown to be 
statistically significant with signal to noise ratios of about 
4:3 and 7:5 respectively.   
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 statistically less degraded than the controls.  The first was the only concentration of TIMP-1 that 
was shown to be potentially significant, and it occurred at the lowest concentration of only 1 
ng/mL.  The mean of this TIMP-1 sample was 1878 ± 62.56 as compared to the controls mean of 
2252 ± 175.9 giving a probability value of < 5%.  Batimistat was shown to reduce degradation at 
concentrations of 100 nM and 1000 nM.  The mean fluorescent value at 100 nM was 1832 ± 
109.2 while the mean value for 1000 nM was 1751.5 ± 158.6 showing that both had < 5% 
probability of being from the control group.   
 
4. Discussion 
 
The signal to noise ratio collected from the first two assays was most acceptable for the 
time period of 4 days at a concentration of DQ collagen at 50 ug/mL.  Both assays showed that 
this result was statistically significant from the control populations, and was visibly more 
distinguishable when plotted due to a larger difference in the mean fluorescent values.  A 
possible explanation for these results is the higher concentration of DQ collagen was likely more 
sensitive to the MMPs secreted by the 3T3 cells since the chances of an MMP finding a binding 
Figure 5. Results of assay testing with inhibitory agents BB-94 (A) and TIMP-1 (B).  BB-94 showed significant results at 100 
nm and 1000 nm with means of 1832 ± 109.2 and 1751.5 ± 158.6 respectively.  TIMP-1 only was shown to be successful in 
MMP inhibition at 1 ng/mL concentration with a mean of 1878 ± 62.56.  The control group represented had a mean of 2252 
± 175.9, which is higher than in either of the previous assays. 
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 site to initiate cleavage were greater.  The 4 day time period allowed the cells to be metabolically 
active longer thereby increasing the concentration of functional MMPs in the model. 
When the inhibitory molecule BB-94 and the MMP inhibitor protein TIMP-1 were 
introduced, the results displayed distinctive patterns of success.  The assay displayed a pattern of 
increasing inhibition effectiveness with an increase in concentration of BB-94.  Batimistat was 
successful in the inhibition of MMPs at concentrations of both 100 nM and 1000 nM.  Although 
these two groups were independent of the control group, they were statistically similar 
potentially implying that the most efficient concentration of BB-94 lies at or around 100 nM with 
diminishing returns resulting from introducing higher concentrations of the drug.  However, 
more testing would be needed to support this hypothesis.  TIMP-1 yielded surprising results with 
only the lowest concentration being statistically successful at inhibition when compared to the 
controls.  A caveat to this result is that the populations of TIMP-1 concentrations were 
statistically indistinguishable from one another with a much more comparable mean than the BB-
94 populations.  The results also do not indicate that increasing the concentration of TIMP-1 will 
have any effect on the inhibition of MMPs within the scope of concentrations tested.   
This particular run of the assay was limited by the inclusion of only fibroblasts within the 
model.  When dealing with ECM reconstruction in vivo, there are other cell types that would 
contribute to the body’s response to an implant, namely macrophages and endothelial cells.  
Macrophages are common responders to all medical implants in vivo since they are mediators of 
the inflammatory response to foreign material [12].  Endothelial cells are found throughout the 
body in various forms, but mainly serve to regulate vasculature systems through protein 
expression including the excretion of MMPs during reconstructive events such as angiogenesis 
[13].  Although the model did not include these cells initially, it is easily adaptable to 
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 accommodate them in future iterations since the structural foam for cell seeding is coated in 
fibronectin, a glycoprotein known to attach both endothelial cells and macrophages [14].  Other 
inhibitory molecules or proteins can likewise be readily incorporated into the assay since the 
setup in not inherently dependent on the choice of inhibitor molecule.  Further testing could also 
be done employing therapeutic MMP inhibitors already approved by the FDA such as Periostat 
[15] or developing therapeutics such as the breast cancer treatment drug Tanomastat [16].  
Overall, the assay proved to be successful in its ability to determine the effectiveness of MMP 
inhibitors as potential protectors to ECM based biomaterials by showing the inhibitory effects of 
BB-94 and TIMP-1. Furthermore, it displays a degree of versatility that will allow it to be 
utilized in successive evaluations of inhibitory molecules and proteins.   
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